Salvage second autologous stem cell transplant for relapsed multiple myeloma in the novel agent era benefits a subset of patients: single-center UK experience.

Huw RichardsSelina J ChavdaWilliam WilsonMarquita CamilleriOliver CohenJackie HorderFiona NewrickXenofon PapanikolaouJonathan SiveLydia LeeRakesh PopatAshutosh WechalekarCharalampia KyriakouKwee YongNeil Rabin

Published in: Leukemia & lymphoma (2021)

Keyphrases

multiple myeloma
stem cells
end stage renal disease
chronic kidney disease
newly diagnosed
ejection fraction
acute myeloid leukemia
peritoneal dialysis
prognostic factors
bone marrow
cell therapy
patient reported outcomes
hodgkin lymphoma
mesenchymal stem cells